In vitro activities of fluconazole and voriconazole against clinical isolates of Candida spp. determined by disk diffusion testing in Turin, Italy.
The in vitro activities of fluconazole and voriconazole against 1,024 clinical isolates of Candida spp. were determined by the agar disk diffusion test using the Clinical and Laboratory Standards Institute (CLSI) M44-A guidelines. The results of this investigation demonstrated the broad-spectrum in vitro activity of voriconazole, relative to that of fluconazole, against yeasts tested, in particular fluconazole-resistant isolates, such as Candida krusei that showed high susceptibility to voriconazole. The situation in Turin, Italy, is quite similar to that of the rest of Italy, reflecting the worldwide trend.
Mandras
Narcisa
N
Department of Public Health and Microbiology, University of Turin, Turin, Italy.
Tullio
Vivian
V
Allizond
Valeria
V
Scalas
Daniela
D
Banche
Giuliana
G
Roana
Janira
J
Robbiano
Francesca
F
Fucale
Giacomo
G
Malabaila
Aurelio
A
Cuffini
Anna Maria
AM
Carlone
Nicola
N
D000935:Antifungal Agents / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects*; D004058:Diffusion; D015725:Fluconazole / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests / Q000379:methods*; D011743:Pyrimidines / Q000494:pharmacology*; D014230:Triazoles / Q000494:pharmacology*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D015725:Fluconazole; D065819:Voriconazole